Vascular Biogenics Ltd. (NASDAQ:VBLT) Analyst Rating Consensus

Vascular Biogenics Ltd. (NASDAQ:VBLT) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1 by 4 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys.

Other Equity analysts have also commented on the company shares. Equity Analysts at the Brokerage Firm, JMP Securities, maintains their rating on the shares of Vascular Biogenics Ltd. (NASDAQ:VBLT). JMP Securities has a Market Outperform rating on the shares. As per the latest research report, the brokerage house lowers the price target to $8 per share from a prior target of $16. The rating by the firm was issued on March 9, 2016.

Vascular Biogenics Ltd. (NASDAQ:VBLT): The stock price is expected to reach $ 18 in the short term. The number of analysts agreeing with this consensus is 4. The higher estimate for the short term price target is at $22 while the lower estimate is at $14. The standard deviation of the price stands at $3.65.

Vascular Biogenics Ltd. (NASDAQ:VBLT) witnessed a decline in the market cap on Tuesday as its shares dropped 0.25% or 0.01 points. After the session commenced at $4.02, the stock reached the higher end at $4.289 while it hit a low of $3.95. With the volume soaring to 829,626 shares, the last trade was called at $3.99. The company has a 52-week high of $12.25. The company has a market cap of $90 million and there are 22,470,321 shares in outstanding. The 52-week low of the share price is $2.76.

Vascular Biogenics Ltd. has dropped 6.34% in the last five trading days, however, the shares have posted positive gains of 23.53% in the last 4 weeks. Vascular Biogenics Ltd. is up 12.39% in the last 3-month period. Year-to-Date the stock performance stands at -24.14%.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Companys program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company is developing VB-111, the lead oncology product candidate from its VTS platform technology, which is a gene-based biologic for the treatment of solid tumor indications, with clinical programs in recurrent glioblastoma (rGBM), thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.